Publicacions en què col·labora amb José Luis Pérez Gracia (11)

2024

  1. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2021

  1. Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

    Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337

2019

  1. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2017

  1. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

    Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694

  2. Tumor-Produced Interleukin-8 Attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs)

    Clinical Cancer Research, Vol. 22, Núm. 15, pp. 3924-3936

2015

  1. Tratamiento del cáncer de próstata en función de la esperanza de vida, la comorbilidad y las guías de práctica clínica

    Anales del sistema sanitario de Navarra, Vol. 38, Núm. 3, pp. 463-464

2001

  1. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial

    Journal of the National Cancer Institute, Vol. 93, Núm. 1, pp. 31-38

  2. High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: A Phase II multicentric trial

    Cancer, Vol. 92, Núm. 10, pp. 2508-2516